Details

Last Funding Type

Series Unknown

Last Funding Money Raised

$7M

Industries

Biotechnology,Health Care,Medical

Founded date

Nov 1, 2008

Number Of Employee

11 - 50

Operating Status

Active

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.